Please assess the completion status of the following clinical trial:

Trial Title: R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with diffuse large B-cell lymphoma according to the WHO classification (anti CD20 labeling)~* Aged from 60 to 65 years.~* Not previously treated.~* Ann Arbor stage II, III, IV.~* ECOG performance status 0 to 2.~* Minimum life expectancy of 3 months.~* Negative HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV) serologies test 4 weeks (except after vaccination).~* Having previously signed a written informed consent.~Exclusion Criteria:~* T-cell lymphoma.~* Any history of treated or non-treated indolent lymphoma. However, patients not previously diagnosed and having a diffuse large B-cell lymphoma with some small cell infiltration in bone marrow or lymph node may be included.~* Central nervous system or meningeal involvement by lymphoma.~* Contra-indication to any drug contained in the chemotherapy regimens.~* Any serious active disease (according to the investigator's decision).~* Poor renal function (creatinine level\>150micromol/l), poor hepatic function (total bilirubin level\>30mmol/l, transaminases\>2.5 maximum normal level) unless these abnormalities are related to the lymphoma.~* Poor bone marrow reserve as defined by neutrophils\<1.5G/l or platelets\<100G/l, unless related to bone marrow infiltration.~* Any history of cancer during the last 5 years with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma.~* Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study.~* Adult patient under tutelage.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- R-ACVBP (Type: EXPERIMENTAL): Rituximab, Doxorubicin, Cyclophosphamide, Vindesine, Bleomycin, Prednisone
- R-CHOP (Type: ACTIVE_COMPARATOR): Rituximab, Doxorubicin, Cyclophosphamide, Vincristine, Prednisone

Based on this trial design, predict the completion outcome and termination type (if applicable).